Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant Continues Its Expansion With Acquisition Of PharmaSwiss

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal will add commercial infrastructure in Central and Eastern Europe and provide tax benefits.

You may also be interested in...



Deals Of The Week: Spectrum/Allos, Amgen/AstraZeneca, Forest/Janssen

Merger and acquisition talk was flying during the week of April 2, while some smaller deals actually got signed on the dotted line.

Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys

Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.

Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility

Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel